A PYMNTS Company

Illumina May Face EU Fine Of 10% Of Turnover Over Grail Deal

By  |  January 11, 2023
Illumina

US life sciences company Illumina is likely to face a fine of 10% of its global annual turnover, the maximum penalty, for closing its takeover of Grail without waiting for EU antitrust approval, people familiar with the matter said.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Last month Illumina defended its case before senior European Commission and national competition officials at a closed hearing but failed to convince them, the people said.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Read more: Illumina Heads To Court Over EU Order To Keep Grail Separate

    Illumina, which last year set aside $453 million for a potential EU fine, said it would appeal against any fine.

    “We disagree that the Commission has jurisdiction to review the GRAIL transaction as well as with the premise of the Commission imposing a fine,” it said in an emailed statement.

    “We have appealed the EU’s jurisdiction and will appeal any decision imposing a fine. Illumina’s merger with GRAIL is pro-competitive and in the best interests of patients in Europe and worldwide,” the company added.